Menu
LAUSANNE, Switzerland – 23 May 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today from the 2016 European Society of Human Genetics Conference (ESHG) in Barcelona, Spain, major company updates that further accelerate cancer diagnosis for patients. First, two new applications for solid tumours are now available via Sophia DDM®, Sophia Genetics’ cutting edge genomics platform. Second, two leading academic figures in oncology have joined Sophia Genetics’ Scientific Board: Dr Aleksandra Filipovic from the Imperial College London, and Peter Wild from the University of Zurich and University Hospital of Zurich (UZH-USZ).
The two new applications available on Sophia DDM® allow users of this cutting edge genomics platform to access advanced diagnostics Next Generation Sequencing (NGS) kit products for breast and ovarian cancer (Sophia DDM®—BRCA Tumor MASTR Plus—SM—MiSeq), colorectal cancers, pancreatic cancers, thyroid follicular tumours, melanoma, and myeloid disorders (Sophia DDM®— SOMATIC 1 MASTR Plus—SM—MiSeq). The first application will be leveraged by clinicians using Sophia DDM® as a diagnostic criterion for treatments involving PARP inhibitor, and the second as a diagnostic criterion when treatment options using BRAF inhibitor or EGFR inhibitor are considered.
The two new applications have been CE-IVD marked by Sophia Genetics. This quality assurance certification represents an important step towards excellence for routine genomic testing in clinical diagnostics, and provides more hospitals and laboratories with access to Sophia DDM® diagnostics applications. In 2014, Sophia Genetics became the first European company to obtain the CE-IVD mark for clinical use of NGS bioinformatics algorithm for routine genetic testing. Today, PEPPERTM and MUSKATTM, its advanced machine learning based algorithms, support 49 different applications. Thirteen of the 49 applications have obtained CE-IVD marking. With these two new CE-IVD marks in oncology applications, Sophia Genetics further demonstrates that NGS based approaches are ripe for routine diagnostics, beyond original hereditary disorder applications.
Since the launch of Sophia DDM®, the advanced genomics platform has become the analytics platform of choice amongst clinicians using diagnostics applications in oncology, hereditary cancers, cardiology, metabolism, and paediatrics. It’s now used by 160 hospitals in 24 countries worldwide. Both Sophia DDM® diagnostics partners and users leverage the analytics platform as an app store, providing access to solutions that accelerate cancer diagnosis for patients. Recently announced partnerships with Swift Biosciences, IDT, and Multiplicom guarantee Sophia DDM® users that genomics data computed by Sophia Genetics offer the highest level of accuracy for diagnostics.
From the 2016 European Society of Human Genetics Conference, Sophia Genetics also announced that two leading academic figures in oncology have joined the company’s Scientific Board: Aleksandra Filipovic, from the Department of Surgery & Cancer of the Faculty of Medicine at the Imperial College London, and Peter Wild, Senior Consultant and Assistant Professor (tenure track) for Systems Pathology at the University of Zurich (UZH) and University Hospital of Zurich (USZ). They join a strong Scientific Board counting the presence of worldwide experts in their fields. They will leverage their expertise to make Data-Driven Medicine a reality for even more patients every day.
Jurgi Cambong, CEO and founder of Sophia Genetics, commented these major announcements. “Something fantastic is happening at Sophia Genetics, and it’s happening fast. Over the past years, Sophia Genetics has triggered rapid advances in clinical genomics and accelerated patients’ diagnoses in 24 countries. Our passion for patients has attracted the best talents from their fields to work on the most pressing healthcare issues of our time, and I am pleased to welcome Aleksandra and Peter to our Scientific Board. Our genomics platform Sophia DDM® is now a must for routine clinical diagnostics, used by 160 hospitals to better and faster inform diagnostics, and help clinicians take the best decisions and provide the best care to their patients. I am looking forward to welcoming even more diagnostics applications to our analytics platform to the benefit of hospitals and laboratories using Sophia DDM®, which will continue to accelerate cancer diagnosis to the ultimate benefit of patients.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
